A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome

Inclusion Criteria: * Male or female over the age of 18 with a diagnosis of SARS and with valid consent will be recruited. Exclusion Criteria: * Subjects with medical conditions that makes the prescription of study medications unsafe are excluded.